Greenwich Lifesciences Inc

Greenwich Lifesciences secures FDA approval for its commercial GP2 lot, clearing a key milestone toward GLSI‑100’s BLA filing and faster breast‑cancer prevention access.

Greenwich Lifesciences completes enrollment of 250 non‑HLA‑A*02 patients in its FLAMINGO‑01 Phase‑III trial for GLSI‑100, a breast‑cancer recurrence immunotherapy.

Greenwich Lifesciences, Inc. is a biotech company dedicated to developing cancer treatments, operating under the Nasdaq stock exchange and committed to improving patient care despite financial challenges.

Greenwich Lifesciences, a biotechnology company, is dedicated to developing cancer treatments, with a focus on serving Texas patients, despite facing financial challenges.

Greenwich Lifesciences, Inc. is a biotech company focused on developing innovative cancer treatments, positioning itself as a beacon of hope in the fight against cancer.

Greenwich Lifesciences, a biotechnology company based in Stafford, Texas, is dedicated to developing and discovering treatments for cancer, with a focus on serving the local community and making a profound impact on patients and the broader healthca…